Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.39 |
| ▸ | MMP9 | P14780 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 4/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227629 | 0.97 | MMP1 (0.39) | MMP1MMP9MMP13LTA4HESR1 | |
| SCHEMBL225171 | 0.92 | ESR1 (0.39) | ESR1ESR2HRH3MAOB | |
| SCHEMBL226135 | 0.92 | MEN1 (0.36) | MMP1MMP9MMP13LTA4HESR1 | |
| SCHEMBL228675 | 0.92 | ESR1 (0.39) | ESR1ESR2HRH3 | |
| SCHEMBL227618 | 0.87 | LTA4H (0.41) | MMP1MMP9MMP13LTA4HESR1 | |
| SCHEMBL226856 | 0.86 | ESR1 (0.46) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL227373 | 0.85 | LTA4H (0.47) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL225986 | 0.84 | HRH3 (0.42) | MMP1MMP9MMP13LTA4HESR1 | |
| SCHEMBL227766 | 0.83 | LTA4H (0.49) | LTA4HESR1ESR2HRH3MAOB | |
| SCHEMBL229972 | 0.83 | LTA4H (0.49) | LTA4HESR1ESR2HRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | MMP1 2500/4885MMP9 4390/4885MMP13 3950/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | MMP1 3169/4885MMP9 4309/4885MMP13 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.